Divarasib Clinical Trials (2026): 12 Studies for Non-Small Cell Lung Cancer & Healthy Participants
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
12 Divarasib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Non-Small Cell Lung Cancer & Healthy Participants) and 4,005 total planned enrollment. 3 Phase 3 Divarasib trials and 2 Phase 2 are listed. 5 Divarasib clinical trials are actively recruiting at 96 U.S. sites across 28 states. Most recent activity: NCT05862285 (Mar 2033).
Where to Participate: All Divarasib Trial Sites in the U.S. (96 sites across 28 states)
Every actively recruiting Divarasibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AK | Alaska Oncology and Hematology | Anchorage99508 | NCT06793215 | Map |
| AZ | City of Hope - Phoenix | Goodyear85338 | NCT06793215 | Map |
| CA | Marin Cancer Care Inc | Greenbrae94904 | NCT06793215 | Map |
| CA | UCLA | Los Angeles90095 | NCT04929223 | Map |
| CA | University of California Los Angeles - Jonsson Comprehensive Cancer Center | Los Angeles90095 | NCT04302025 | Map |
| CA | Hoag Memorial Hospital | Newport Beach92658 | NCT06793215 | Map |
| CA | The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange | Orange92868 | NCT04302025 | Map |
| CA | Palo Alto Medical Foundation Research Center | Palo Alto94301 | NCT06793215 | Map |
| CA | Sutter Institute for Medical Research | Roseville95661 | NCT06793215 | Map |
| CA | UC Davis Comprehensive Cancer Center | Sacramento95817 | NCT04302025 | Map |
| CA | California Pacific Medical Center | San Francisco94115 | NCT06793215 | Map |
| CO | UC Health Oncology Research | Colorado Springs80909 | NCT06793215 | Map |
| CO | Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System | Fort Collins80528 | NCT06793215 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Lone Tree80124 | NCT04929223 | Map |
| CT | Hartford Hospital | Hartford06102-5037 | NCT06793215 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT04929223 | Map |
| CT | Yale Cancer Center | New Haven06511 | NCT04302025 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT05789082 | Map |
| DC | MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) | Washington D.C.20007 | NCT04302025 | Map |
| FL | Florida Cancer Specialists - SOUTH - SCRI - PPDS | Fort Myers33901-8108 | NCT05789082 | Map |
| FL | Florida Cancer Specialists - SOUTH - SCRI - PPDS | Fort Myers33901-8108 | NCT06793215 | Map |
| FL | University of Florida Health at Shands | Gainesville32610 | NCT06793215 | Map |
| FL | BioResearch Partner | Hialeah33013 | NCT06793215 | Map |
| FL | Memorial Healthcare System - Memorial Regional Hospital | Hollywood33021 | NCT06793215 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT06793215 | Map |
| FL | Ascension Sacred Heart | Pensacola32504 | NCT06793215 | Map |
| FL | Florida Cancer Specialists - NORTH - SCRI - PPDS | St. Petersburg33705-1400 | NCT05789082 | Map |
| FL | Florida Cancer Specialists - NORTH - SCRI - PPDS | St. Petersburg33701 | NCT06793215 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04302025 | Map |
| FL | Florida Cancer Specialists - EAST - SCRI - PPDS | West Palm Beach33401-3406 | NCT05789082 | Map |
| FL | Florida Cancer Specialists - EAST - SCRI - PPDS | West Palm Beach33401-3406 | NCT06793215 | Map |
| GA | Piedmont Cancer Institute, PC | Atlanta30318 | NCT06793215 | Map |
| GA | City of Hope® Atlanta | Newnan30265 | NCT06793215 | Map |
| GA | Summit Cancer Care PC | Savannah31405 | NCT06793215 | Map |
| ID | St. Luke's Cancer Institute | Boise83712 | NCT06793215 | Map |
| IL | Illinois Cancer Specialists | Arlington Heights60005 | NCT04929223 | Map |
| IL | Northwestern University | Chicago60611 | NCT04302025 | Map |
| IL | Affiliated Oncologists, LLC | Chicago Ridge60415 | NCT06793215 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT04302025 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT04302025 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT04302025 | Map |
| IL | City of Hope® Cancer Center Chicago | Zion60099 | NCT06793215 | Map |
| IA | Mission Cancer + Blood - IMMC | Des Moines50309 | NCT06793215 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06793215 | Map |
| LA | Mary Bird Perkins Cancer Ctr | Baton Rouge70809 | NCT04929223 | Map |
| MD | Saint Agnes Hospital - Baltimore - Hunt - PPDS | Baltimore21229-5201 | NCT06793215 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04302025 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06793215 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT04302025 | Map |
| MI | Profound Research, LLC | Farmington Hills48334 | NCT06793215 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT04302025 | Map |
| MN | Mayo Clinic Rochester | Rochester55902 | NCT04929223 | Map |
| MO | Ellis Fischel Cancer Center | Columbia65201 | NCT04302025 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT06793215 | Map |
| MO | Siteman Cancer Center - Washington University Medical Campus | St Louis63108 | NCT04302025 | Map |
| NE | NHO Revive Research Institute | Lincoln68506 | NCT06793215 | Map |
| NH | Dartmouth Hitchcock Medical Center | Lebanon03756 | NCT04302025 | Map |
| NM | San Juan Oncology Associates | Farmington87401 | NCT06793215 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05789082 | Map |
| NY | New York Cancer & Blood Specialists - New Hyde Park | New Hyde Park11042-1116 | NCT04929223 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT04302025 | Map |
| NY | Laura and ISAAC Perlmutter Cancer Center at NYU Langone. | New York10016 | NCT04302025 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04302025 | Map |
| NY | Mount SInai Medical Center | New York10029 | NCT05789082 | Map |
| NY | New York Cancer and Blood Specialists-Central Park Hematology & Oncology | New York10028 | NCT04929223 | Map |
| NY | NYU Cancer Center | New York10016 | NCT05789082 | Map |
| NY | New York Cancer & Blood Specialists | Port Jefferson Station11776 | NCT04929223 | Map |
| NY | Montefiore Einstein Cancer Center | The Bronx10461 | NCT06793215 | Map |
| NY | Montefiore Medical Center - Montefiore Medical Park | The Bronx10461 | NCT05789082 | Map |
| NY | New York Cancer & Blood Specialists - Bronx | The Bronx10469-5930 | NCT04929223 | Map |
| NY | Clinical Research Alliance | Westbury11590 | NCT06793215 | Map |
| NC | Firsthealth of The Carolinas | Pinehurst28374 | NCT06793215 | Map |
| OH | Ohio State University | Columbus43210 | NCT04302025 | Map |
| OH | Ohio State University | Columbus43210 | NCT06793215 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06793215 | Map |
| PA | St. Luke's University Health Network | Bethlehem18015 | NCT06793215 | Map |
| PA | Allegheny Cancer Center | Pittsburgh15212 | NCT06793215 | Map |
| PA | Reading Hospital - McGlinn Cancer Institute | West Reading19611 | NCT06793215 | Map |
| TN | Baptist Cancer Center | Memphis38120 | NCT06793215 | Map |
| TN | Baptist Clinical Research Institute | Memphis38120 | NCT04302025 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT04929223 | Map |
| TX | Texas Oncology - Northeast Texas | Denton76201 | NCT04929223 | Map |
| TX | Renovatio Clinical - El Paso | El Paso79915 | NCT06793215 | Map |
| TX | JPS Health Network | Fort Worth76104 | NCT06793215 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05789082 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030-4000 | NCT06793215 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030-4008 | NCT04302025 | Map |
| TX | Community Clinical Trials | Kingwood77339 | NCT06793215 | Map |
| TX | Texas Tech Health Science Center | Lubbock79415 | NCT06793215 | Map |
| TX | Renovatio Clinical | The Woodlands77380 | NCT06793215 | Map |
| TX | University of Texas Health Center at Tyler | Tyler75708 | NCT06793215 | Map |
| TX | Texas Oncology - Gulf Coast | Webster77598-4420 | NCT04929223 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc | Blacksburg24060 | NCT05789082 | Map |
| VA | Virginia Cancer Specialists (Fairfax) - USOR | Fairfax22031 | NCT04302025 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT05789082 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT06793215 | Map |
Divarasib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 4 | 5 | |
| P1/P2 | 1 | 1 | ||
| P2 | 1 | 1 | 2 | |
| P2/P3 | 1 | 1 | ||
| P3 | 2 | 1 | 3 |
Recruiting Divarasib clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05862285 | UmbrellaMAXA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | P3 | Cancer | 100 | Jun 2023 |
| NCT05789082 | KRAScendo 170A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | P1/P2 | Non-Small Cell Lung Cancer | 320 | Jun 2023 |
| NCT06793215 | Krascendo 2A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | P3 | Non-Small Cell Lung Cancer | 600 | Oct 2025 |
| NCT04929223 | INTRINSICA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | P1 | Metastatic Colorectal Cancer | 542 | Oct 2021 |
| NCT04302025 | NAUTIKA1A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | P2 | Non-small Cell Lung Cancer | 99 | Nov 2020 |
Divarasib clinical trials by indication
Non-Small Cell Lung Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05789082 | KRAScendo 170 | P1/P2 | recruiting | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation |
| NCT06793215 | Krascendo 2 | P3 | recruiting | A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer |
| NCT06497556 | Krascendo 1 | P3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT03178552 | B-FAST | P2/P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) |
Healthy Participants (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06835465 | — | P1 | completed | A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants |
| NCT06690138 | — | P1 | completed | A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants |
| NCT06677957 | — | P1 | completed | A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06734208 | — | P1 | completed | A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function |
Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05862285 | UmbrellaMAX | P3 | recruiting | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study |
Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04929223 | INTRINSIC | P1 | recruiting | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04589845 | TAPISTRY | P2 | active not recruiting | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study |
Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04302025 | NAUTIKA1 | P2 | recruiting | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) |
Divarasib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| UmbrellaMAX | NCT05862285 | P3 | recruiting | Cancer | 100 | — |
| Krascendo 2 | NCT06793215 | P3 | recruiting | Non-Small Cell Lung Cancer | 600 | — |
| Krascendo 1 | NCT06497556 | P3 | active not recruiting | Non-Small Cell Lung Cancer | 338 | — |
| TAPISTRY | NCT04589845 | P2 | active not recruiting | Solid Tumors | 920 | — |
| NAUTIKA1 | NCT04302025 | P2 | recruiting | Non-small Cell Lung Cancer | 99 | — |
All Divarasib trials (12)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05862285 | UmbrellaMAX | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | P3 | recruiting | 100 | Hoffmann-La Roche | Jun 2023 |
| NCT04589845 | TAPISTRY | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | P2 | active not recruiting | 920 | Hoffmann-La Roche | Jan 2021 |
| NCT05789082 | KRAScendo 170 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | P1/P2 | recruiting | 320 | Hoffmann-La Roche | Jun 2023 |
| NCT06793215 | Krascendo 2 | A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | P3 | recruiting | 600 | Hoffmann-La Roche | Oct 2025 |
| NCT04929223 | INTRINSIC | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | P1 | recruiting | 542 | Hoffmann-La Roche | Oct 2021 |
| NCT04302025 | NAUTIKA1 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | P2 | recruiting | 99 | Genentech, Inc. | Nov 2020 |
| NCT06497556 | Krascendo 1 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | P3 | active not recruiting | 338 | Hoffmann-La Roche | Sep 2024 |
| NCT03178552 | B-FAST | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | P2/P3 | active not recruiting | 1,000 | Hoffmann-La Roche | Sep 2017 |
| NCT06734208 | A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function | P1 | completed | 31 | Genentech, Inc. | Jan 2025 | |
| NCT06835465 | A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants | P1 | completed | 18 | Genentech, Inc. | Feb 2025 | |
| NCT06690138 | A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants | P1 | completed | 18 | Genentech, Inc. | Nov 2024 | |
| NCT06677957 | A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants | P1 | completed | 19 | Genentech, Inc. | Nov 2024 |
Divarasib clinical trials: frequently asked questions
- How many Divarasib clinical trials are there?
- 12 Divarasib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 4 are marked completed.
- Are Divarasib clinical trials recruiting in 2026?
- Yes — 5 Divarasib trials are actively recruiting in 2026, with 96 U.S. sites across 28 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Divarasib being studied for?
- Divarasib is being studied for Non-Small Cell Lung Cancer, Healthy Participants, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer, Cancer and 3 more. The trials are grouped by indication on this page.
- What phase is Divarasib in?
- Divarasib clinical trials span 3 Phase 3, 2 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Divarasib clinical trials?
- The lead sponsor across the most Divarasib trials is Hoffmann-La Roche, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Divarasibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: